Torsten Rüdiger Goesch

Develops and manufactures drugs related to immunology, neurobiology and oncology

Rosetta Capital invests in early and mid-stage growth companies in biotechnology-related sectors. The firm invest in acquisition financing and spin-off transactions.

Functions as a College/University

TRG Investors focuses on value-added asset management in underserved asset classes. The firm manages private investment funds using two strategies. The first strategy provides tactical asset allocation across all traditional asset classes, including domestic equities and fixed-income, international equities and fixed-income, real estate, currencies and commodities. The second strategy seeks to provide low correlation and high absolute returns by investing in small and micro-cap public companies and small private company buyouts with a geographical focus on the Upper Midwest. TRG Investors also invests alongside management in private equity transactions. They make both majority and minority investments and are willing to syndicate with other like-minded investors. The firm invests in profitable companies with solid growth potential that are led by exceptional management. TRG Investors primarily purchases equity in their private company investments, but will consider subordinated debt positions in certain situations.

Develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients

Develops and manufactures proprietary formulations for inflammatory and neurological indications

Provides marketing solutions to the health care industry

Operates as a biotechnology company which develops antifungal drugs for the treatment of severe invasive fungal infections